美罗培南药动学/药效学及特殊人群用药的研究进展
x

请在关注微信后,向客服人员索取文件

篇名: 美罗培南药动学/药效学及特殊人群用药的研究进展
TITLE: Research progress in pharmacokinetics/pharmacodynamics and drug use of meropenem in special population
摘要: 美罗培南是治疗多药耐药菌感染的首选药物,已广泛应用于临床,但特殊人群的生理病理特征会对美罗培南的药动学/药效学(PK/PD)参数产生影响,临床应用时需根据患者特征制定个体化给药方案。因此,本文总结了美罗培南在特殊人群中的PK/PD特点和应用,推荐美罗培南在儿童患者中给予10~40mg/kg,q8h;在老年患者中给予1g,q8~12h;在肾功能不全、接受连续静脉-静脉血液滤过和连续静脉-静脉血液透析的患者中给予0.75g,q8h;在肾功能亢进患者中给予1g,q8h延长输注至3h或2g,q8h;在肝硬化患者中给予2g负荷剂量后再给予1g,q8h。
ABSTRACT: Meropenem is the first choice for the treatment of multi-drug-resistant bacterial infections, which has been widely used in clinical practice. However, the physiological and pathological characteristics of special populations have a significant impact on the pharmacokinetics/pharmacodynamics (PK/PD) parameters of meropenem, so it is necessary to develop individualized drug administration plan according to the characteristics of patients in clinical application. Therefore, this paper summarizes PK/PD characteristics and application of meropenem in special population, and recommends the dosage of meropenem as follows: 10-40 mg/kg, q8 h for children; 1 g, q8-12 h for elderly patients; 0.75 g, q8 h for the patients with renal insufficiency who received continuous veno-venous hemofiltration and continuous veno-venous hemodialysis; 1 g, q8 h prolonged infusion until 3 hours or 2 g, q8 h for patients with hyperrenal function; 1 g, q8 h after 2 g loading dose for patients with cirrhosis.
期刊: 2023年第34卷第13期
作者: 徐红艳;黄健;武阿龙;徐丙发
AUTHORS: XU Hongyan,HUANG Jian,WU Along,XU Bingfa
关键字: 美罗培南;药动学;药效学;药物相互作用;治疗药物监测
KEYWORDS: meropenem; pharmacodynamics; pharmacokinetics; drug interaction; therapeutic drug monitoring
阅读数: 220 次
本月下载数: 8 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!